EQ

Equillium, Inc.

Pharmaceutical Preparations · SIC 2834CIK 1746466Held by 2 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

—

Net Income FY2025

$(22.0M)

EPS (Basic, as reported)

$-0.39

Net Margin FY2025

—

ROE FY2025

-78.3%

Total Equity

$29.0M

Shares Out

63M

Business description

Equillium, Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2017–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 16 → 41 +60.1% CAGR

Fiscal yearFY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024⚑FY2025

Revenue—————163641—

Research & development—(5)(18)(19)(26)(38)(37)——

General & administrative—(4)(9)(10)(11)(17)(14)(12)(11)

Total operating expenses—(9)(27)(30)(38)(78)(51)(49)(24)

Operating income—(9)(27)(30)(38)(62)(15)(8)(24)

Interest expense—(3)0(1)(1)(1)0——

Interest & investment income—01000211

Other income (expense), net—(5)10(1)02——

Pre-tax income—(13)(26)(30)(39)(62)(13)(8)(22)

Income tax expense———000(1)00

Net income—(13)(26)(30)(39)(62)(13)(8)(22)

EPS — basic————($1.36)($1.85)($0.38)($0.23)($0.39)

EPS — diluted————($1.36)($1.85)($0.38)($0.23)($0.39)

Shares outstanding — basic (M)————2934353557

Shares outstanding — diluted (M)————2934353557

⚑ Weighted-average shares changed ×1.63 between FY2024 and FY2025 — a large issuance or reduction. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.